Antonella Scaglione, PhD
About Antonella Scaglione, PhD
Antonella Scaglione, PhD, is a Research Scientist at NYU Langone Health specializing in viral vector platforms and vaccine development.
Title
Antonella Scaglione, PhD, currently holds the position of Research Scientist at NYU Langone Health.
Company
Antonella Scaglione works at NYU Langone Health, where she began her tenure in 2020. The institution is located in the New York City Metropolitan Area.
Previous Positions
Antonella Scaglione has held several significant positions in her career. She was a Postdoctoral Research Associate at the Advanced Science Research Center, GC/CUNY from 2018 to 2020, and a Postdoctoral Fellow at the Icahn School of Medicine at Mount Sinai from 2016 to 2018. Additionally, she spent six months in 2016 as a Short Postdoctoral Fellow at the University of Rome 'La Sapienza' and gained experience as a Biostruct-X Fellow at Paul Scherrer Institut (PSI) in Switzerland. She has also conducted research as a Visiting PhD Fellow at Columbia University Medical Center and as a Trainee PhD Fellow at EMBL in France.
Education and Expertise
Antonella Scaglione holds a Doctor of Philosophy (PhD) in Biochemistry from Sapienza Università di Roma, where she studied from 2012 to 2015. She also achieved a Master's degree in Neurobiology from the same institution, completing her studies from 2010 to 2012. Furthermore, Scaglione earned a Bachelor's degree in Biological Sciences from the University of Naples Federico II, where she studied from 2006 to 2010. Her academic background has equipped her with extensive knowledge and expertise in biochemistry, neurobiology, and biological sciences.
Research Activities
Antonella Scaglione has contributed to various research projects throughout her career. She developed a novel RNA alphavirus-based platform approach for vaccine development, which is currently under peer-review on the bioRxiv portal. She has engaged in oncolytic immunotherapy studies using Sindbis as a viral vector platform, focusing on in vivo cancer models in mice. Additionally, she has utilized immunologic and virological approaches to understand virus mechanisms of action in tumor microenvironments and designed mechanistic and translational studies to advance viral vector platforms to human clinical trials. Scaglione also established and optimized in vitro and diagnostic assays for developing safer vaccine platforms for SARS-CoV-2 and other infectious agents.